Challenger in the growing Swedish security market Streamlining should highlight Swedish operations 7...
In our view, earnings will become more stable, as the company seems satisfied with its structure aft...
We cut '25e-'26e adj. EBITA by 10-1% Utilisation should pick up in H2'25e '25e EV/EBITA of ~8x What...
Q4e soft, market remains muted Lower range of targets likely Recovery postponed, '25 also slow Q4e ...
Consti’s Q4 was roughly in line with our estimates as net sales were a touch higher and profitabilit...
Redeye gives a short comment on the news that Saniona’s partner Medix will file a final version of T...
Weak order trend broken, orders +29% y-o-y, above our flat estimate '25e-'26e orders +7%, sales +4%,...
Redeye takes a positive stance on Teneo AI raising SEK60m from a directed share issue.
Investors House reported Q4 revenues of EUR 2.8m, 7% above our estimate.
After a period of steady increase in both European Idefirix sales and patient usage, Hansa records a...
Plejds nettoomsättning för det fjärde kvartalet 2024 uppgick till 204,0 MSEK (161,9), en ökning med ...
Redeye makes positive estimate adjustments on the back of I-Tech’s record Q4 report delivering y/y g...
Redeye updates its estimates ahead of Arise’s Q4 report, which is due on Valentine’s Day (Friday 14 ...
Redeye argues that AVTECH has secured double-digit growth following the LATAM Airlines agreement sig...
Redeye retains its positive stance towards Hexatronic following a Q4 report that matches our expecta...
Strong Q4 driven by Engineered Solutions EBITA up 2% organically, but cancelled out by weaker FX Sha...
We trim '25e-'26e ARR by 1% on continued macro weakness Still awaiting a return in B2C business mome...
Conditions remain stable but unfavourable We cut '25e-'26e sales by 9-8% due to the divestment '25e-...
Ökad försäljning och lönsamhet EQL Pharma ökade nettoomsättningen med 31,3 procent, främst drivet av...
DT already achieved a strong year in terms of profitability, and although earnings growth may no lon...
